LifeAssays Inc. to Present at Windhover Information and Medtech Insight's ``Investment In Innovation'' Conference.BOSTON -- LifeAssays(R) Inc. will be presenting on October 21 (10:30 AM) at Windhover wind·hov·er n. Chiefly British A kestrel. Information and Medtech Insight's Prestigious "Investment In Innovation" Event, taking place October 21-22, 2004 at the Westin Copley Place Hotel in Boston, Massachusetts. E[acute accent]The growing governmental and public interest in preventive long-term health measures has created an expanding market for mass screening and Point-of-Care testing point-of-care testing Lab medicine The analysis of clinical specimens as close as possible to the Pt, including bedside, ward–unit, or 'stat' regional response labs that service specified areas–eg, the ER or ICU . Cover page articles such as the one found in the March issue of the magazine TIME puts the focus on low-range C reactive protein C reactive protein Lab medicine A 120 kD polypeptide of the pentraxin family which is produced by the liver during inflammation and detectable in serum in various conditions particularly during acute immune responses, named for its ability to bind the C (CRP C-reactive protein (CRP) A protein present in blood serum in various abnormal states, like inflammation. Mentioned in: Pelvic Inflammatory Disease CRP, n.pr See C-reactive protein. ) testing. This increased governmental and public awareness will drive an increased demand for testing of several substances in addition to the already well established cholesterol tests. E[acute accent]LifeAssays(R) is a Swedish blood diagnostics company developing and producing the next generation of mass screening and Point-of-Care tests, which are based on a unique and patent protected magnetic sensing technology. The inventor behind this technology is Dario Kriz. The kits and instrumentation allows fast and easy diagnosis of proteins, hormones and bacteria in blood or urine samples. The first tests developed by LifeAssays(R) are targeting a cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease risk indicator (high sensitive CRP) and a renal dysfunction risk indicator (Cystatin C and Albumin). Comparison studies on patient samples from Lund University Hospital (Sweden) and the Academic Hospital of Uppsala (Sweden) have shown very promising results. E[acute accent]The overall US POC (Proof Of Concept) See PoC exploit. POC - Point Of Contact market was estimated to be $828 million in 2001 and is expected to increase to $1,915 million in 2001 (TriMark Publications, 2003). The POC market consists of two segments: hospital testing, which is an extension of the hospital centralized laboratory and decentralized de·cen·tral·ize v. de·cen·tral·ized, de·cen·tral·iz·ing, de·cen·tral·iz·es v.tr. 1. To distribute the administrative functions or powers of (a central authority) among several local authorities. testing which consists of physician office labs, nursing homes, pharmacies and other non-institutional settings. It is the decentralized testing which will be the target market for the company's products. This market segment was estimated to be worth $276 million in the US alone during 2001 and the drive for cost containment cost containment, n the features of a dental benefits program or of the administration of the program designed to reduce or eliminate certain charges to the plan. in the health care market will cause this segment to grow by 20% over the next few years. E[acute accent]LifeAssays(R) is a publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. (Ticker EURI B) on the Swedish stock exchange, Nordic Growth Market, in Stockholm. The company stocks are distributed between a venture capital company, the European Institute of Science, (holding 23% of the capital stock, www.euris.org) and approximately 2,000 shareholders (with each less than 2% of the capital stock). LifeAssays(R) is looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. strategic partners or investors to help with the development of a complete testing system validated for mass screening or Point-of-Care applications. The present shareholders are interested in acquisition discussions with industrial or financial partners. E[acute accent]About Medtech Insight E[acute accent]Medtech Insight's "Investment In Innovation" conferences are considered the premier forum for senior executives in the investment and medical technology community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. Medtech Insight, which was recently acquired by Windhover Information Inc. (www.windhover.com), publisher of IN VIVO in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. : The Business & Medicine Report, Start-UP: Windhover's Review of Emerging Technologies, and IN VIVO EuropeRx, offers a wide variety of products and services for the medical technology executive. In addition to conferences, the company publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, as well as analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the Boston conference or for more information on Medtech Insight, please call Scott Pantel at (949) 219-0150 or (888) 290-2225 toll-free in the U.S., e-mail sales@medtechinsight.com, or visit http://www.medtechinsight.com/in3-12.html. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion